PA-ABEC
2.6.2022 15:35:07 CEST | Business Wire | Press release
ABEC , a global provider of engineered solutions and services for biotech manufacturing, today announced that mAbxience will equip their state-of-the-art cGMP facility in León, Spain with an additional ABEC 4,000L CSR bioreactor . Following the successful delivery of the first 4,000L CSR bioreactor in 2021 , mAbxience again selected ABEC’s innovative single-use technology to increase its CDMO business and capacity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220602005037/en/
In April 2022, and after being approved in Europe, Canada, and Japan among others, the U.S. Food and Drug Administration (FDA) approved a Biologics License Application (BLA) for bevacizumab-maly , which was developed by mAbxience and represents the third biosimilar approved in the U.S. Marrying innovation with cutting-edge R&D technology, mAbxience is committed to improving patient access to vital treatments. With the additional 4,000L CSR bioreactor, mAbxience will realize even greater cell culture productivity and faster process transfer scale-up.
“mAbxience’s continued growth in the biosimilar market speaks to the value of our strategic partnerships, such as with ABEC ,” said Emmanuelle Lepine, CEO of mAbxience. “As we look to the future of healthcare, we are excited to be on the forefront of sustainable practices that will improve access to critical medicines.”
“ABEC continues to lead the industry in bringing scale and productivity to single-use manufacturing,” said Scott Pickering, Chairman, and CEO, ABEC. “We are proud to continue to support mAbxience’s growth with our innovative CSR technology.”
About ABEC
Since 1974, ABEC has been a global leader in delivering engineered process solutions and services for manufacturing in the biotech industry. The majority of the world's pharmaceutical and biotech companies are ABEC customers; with many of today's leading therapies manufactured by processes and equipment engineered, manufactured, installed, and serviced by ABEC. ABEC's unique value is based on long experience, complete in-house capabilities, a custom, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC's turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. To learn more about ABEC, visit abec.com , email info @ab ec.co m and follow us on LinkedIn .
About mAbxience
MAbxience is a fully integrated global biopharmaceutical company specialising in the development, manufacture and commercialization of monoclonal antibodies and CDMO services, and forms part of the pharmaceutical group Insud Pharma. Founded in 2010, mAbxience operates three state-of-the-art facilities, located in Spain and Argentina. mAbxience is working on several biopharmaceutical products spanning to different therapeutic areas. In 2014 mAbxience launched its first biosimilar, Rituximab (Product Code: RTXM83-MB01), which is now approved and marketed in a range of markets worldwide. Its second product, Bevacizumab (Product Code: BEVZ92-MB02), was first developed and launched in Latin America in 2016. mAbxience is committed to the quality, safety and efficacy of its medicines. The mAbxience team is passionate about patient care and expanding access to its biopharmaceutical medicines all over the world. The Company's mission is to improve patient access to quality treatments for conditions that require costly medications and positively contributing to the sustainability of healthcare systems. The Insud Pharma Group was founded by Dr. Hugo Sigman and Dr. Silvia Gold and has over 40 years' experience in the pharmaceutical sector and employs over 6,000 professionals worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom